Cognition Therapeutics Reports Q2 2024 Financial Results and Positive Phase 2 SHINE Trial Data

COGNITION THERAPEUTICS INC

2024-Q2 EPS reported -$0.44

Phase 2 SHINE trial showed ~40% mean improvement in ADAS-Cog 11 vs placebo in mild-to-moderate Alzheimer's.
Cash and equivalents $28.5M as of June 30, 2024; NIA grant funds remaining $57.3M.
Net loss $7.0M for Q2 2024 vs $4.7M for Q2 2023.
Topline results from SHIMMER study in DLB expected by year-end 2024.
Company planning next phase of Alzheimer's development after SHINE results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.